Kythera Biopharmaceuticals, Inc. was a big mover last session, as the company saw its shares surge by more than 25% on the day. The move came on solid volume too, as far more shares changed hands than in a normal session. This continues the recent uptrend for the company, as the stock has gained more than 78% in the past one-month time frame.
The company has seen two negative revisions and a single positive revision in the past two months. Also, its earnings consensus has moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent rally can last.
KYTH currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Some better performing Med-BioMed/Gene stocks include Actelion Ltd. (ALIOF - Snapshot Report) , Affymetrix Inc. and Gilead Sciences Inc. (GILD - Analyst Report) . All these stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>